Fang Feng

发表

Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR

Tao Zhang, Xia Wang, Honglin Li, 2019 .

C-H Trifluoromethylation of 2-Substituted/Unsubstituted Aminonaphthoquinones at Room Temperature with Bench-Stable (CF3SO2)2Zn: Synthesis and Antiproliferative Evaluation.

Jian Ding, Lin-jiang Tong, Xiaofei Zhang, 2017, The Journal of organic chemistry.

Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as novel and potent TBK1 inhibitors: design, synthesis, biological evaluation, and molecular docking study

Tongchao Liu, B. Xiong, Hua Xie, 2022, Journal of enzyme inhibition and medicinal chemistry.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

7α,8α-Epoxynagilactones and their glucosides from the twigs of Podocarpus nagi: Isolation, structures, and cytotoxic activities.

Sheng Yao, Jian Ding, Lin-jiang Tong, 2018, Fitoterapia.

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo

K. Yu, Yi Chen, Jian Ding, 2023, Journal of Cancer.

Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S.

Xia Wang, Honglin Li, Zhenjiang Zhao, 2019, ACS medicinal chemistry letters.

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

Kai Yu, Yi Chen, Jian Ding, 2021, Cancer science.

Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.

Honglin Li, Jiankun Lyu, Zhenjiang Zhao, 2018, Journal of medicinal chemistry.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Design, Synthesis, and Evaluation of (R)-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor.

Lin-jiang Tong, Hua Xie, Qian Li, 2023, Journal of medicinal chemistry.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

Lin-jiang Tong, Hua Xie, Yan-yan Shen, 2023, Acta pharmaceutica Sinica. B.

ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Drug Discovery.

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation

Lin-jiang Tong, Huancheng Zhou, Gang Bai, 2024, Signal transduction and targeted therapy.

Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.

Lin-jiang Tong, Tao Zhang, Yan Li, 2024, Acta pharmacologica Sinica.